Pursuant to a special resolution passed by shareholders on Oct. 27, 2023, the company has consolidated its capital on a one-new-for-nine-old basis. The name of the company has not been changed.
Effective at the opening, Friday, Nov. 10, 2023, the common shares of the company will commence trading on the TSX Venture Exchange on a consolidated basis. The company is classified as a pharmaceutical company.
Postconsolidation
Capitalization: unlimited shares with no par value, of which
1,998,854 shares are issued and outstanding
Escrow: nil shares subject to escrow
Transfer agent: TSX Trust Company
Trading symbol: XRTX (unchanged)
Cusip No.: 98420Q 30 6 (new)
© 2025 Canjex Publishing Ltd. All rights reserved.